Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Herceptin Market Forecast: What Value Will The Market Reach By 2030?
Significant expansion has been observed in the herceptin market size during recent years. The market is projected to increase from $7.48 billion in 2025 to $7.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. The historical growth can be ascribed to several factors, including the expansion of her2-positive cancer diagnosis, widespread clinical acceptance of trastuzumab, growth in oncology infusion infrastructure, availability of biologic manufacturing capabilities, and the integration of herceptin into standard treatment guidelines.
The herceptin market is poised for significant expansion over the coming years, with expectations to reach $9.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.8%. This anticipated growth is primarily fueled by escalating biosimilar competition, a growing demand for cost-effective biologic therapies, the broadening of targeted oncology pipelines, the increasing adoption of individualized cancer treatments, and heightened investment in biologic drug innovation. Key developments during this forecast period are expected to include a greater embrace of biosimilar trastuzumab products, the expanding utilization of subcutaneous formulations, the diversification of combination therapy regimens, an intensified focus on economical biologic treatments, and improved monitoring of treatment outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Herceptin Market Growth Factors Behind Sustained Expansion
The rising prevalence of breast cancer is anticipated to fuel the expansion of the herceptin market in the future. This malignancy originates within the breast cells, typically commencing in the milk ducts or lobules. Common forms encompass invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. A contributing factor to the surge in breast cancer cases involves lifestyle modifications, including heightened alcohol intake, inadequate nutrition, and insufficient exercise, all of which elevate the risk. With a growing number of individuals receiving breast cancer diagnoses, especially those with HER2-positive conditions, the need for potent targeted treatments like herceptin consistently increases. For example, the American Cancer Society, a US-based cancer organization, estimated in January 2025 that 319,750 new breast cancer cases are projected for 2025, alongside an estimated 42,680 fatalities from the illness. Consequently, the heightened occurrence of breast cancer is propelling the growth of the herceptin market.
Herceptin Market Segment Analysis Spotlighting Growth Areas
The herceptin market covered in this report is segmented –
1) By Product: Biologic, Biosimilar
2) By Application: Breast Cancer, Gastric Cancer
3) By Payer: Commercial And Private, Public
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy
Subsegments:
1) By Biologic: Intravenous (IV) Biologics, Subcutaneous (SC) Biologic
2) By Biosimilar: Intravenous (IV) Biosimilars, Subcutaneous (SC) Biosimilars
Herceptin Market Strategic Trends: What Defines The Next Growth Phase?
Key players within the herceptin market are actively developing innovative treatment options, including advanced biosimilar products, to expand patient access and enhance therapeutic outcomes for individuals with HER2-positive cancers. These innovative biosimilar products represent highly comparable versions of established biologic drugs, developed using sophisticated biotechnology to ensure similar levels of safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, secured approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to herceptin (trastuzumab), intended for the management of HER2-overexpressing breast and gastric cancers. Such biosimilars, including HERCESSI, demonstrate equivalent efficacy and safety when compared to their reference biologics, while also potentially providing more cost-effective treatment solutions.
Herceptin Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the herceptin market are Roche Holding AG, Pfizer Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Biocon Limited, Dr. Reddy’s Laboratories, Celltrion Inc., Samsung Biologics, Fresenius Kabi, Intas Pharmaceuticals Ltd, Zydus Lifesciences Ltd, AryoGen Pharmed, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd, Alvotech, Coherus BioSciences, BioXpress Therapeutics, Amneal Pharmaceuticals, Novartis AG
View The Full Herceptin Market Report:
Herceptin Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the herceptin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









